ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Heptares, Cubist Join On GPCR Research

by Rick Mullin
January 14, 2013 | APPEARED IN VOLUME 91, ISSUE 2

Heptares Therapeutics and Cubist Pharmaceuticals will collaborate on the discovery of new therapies targeting G protein-coupled receptors (GPCRs) using Heptares’ drug discovery platform. Under the agreement, Cubist will hold exclusive worldwide rights to develop and commercialize drug candidates identified by the partners. Cubist will pay Heptares $5.5 million up front and up to $4 million in research funding, plus milestones and royalties, for the first drug target. GPCRs are membrane proteins involved in a broad range of biological processes and diseases.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment